MetaCap

LB Pharmaceuticals (LBRX) vs Ocular Therapeutix (OCUL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

LB Pharmaceuticals (LBRX) has outperformed Ocular Therapeutix (OCUL) over the past year, gaining 153.4% versus a loss of 54.5%. LB Pharmaceuticals is the larger company by market cap ($1.26 billion vs $1.23 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LBRX+153.42%OCUL-54.49%
+237%+84%-68%
Nov 21, 20251 yearNov 20, 2026
LBRX+131.25%OCUL-56.52%
+206%+69%-69%
Sep 8, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LBRX versus OCUL key metrics
MetricLBRXOCUL
Share price$38.85$5.57
Market cap$1.26B$1.23B
1-day change-2.97%-4.95%
YTD return+74.53%-54.12%
1-year return+153.42%-54.49%
5-year return—-14.83%
EPS (TTM)$-1.12$-1.44
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$51.95M
Revenue growth (YoY)—-18.47%
Net income (latest FY)$-25.20M$-265.94M
Gross margin—87.35%
Operating margin—-519.75%
Net margin—-511.90%
52-week high$50.16$16.44
52-week low$15.55$5.54
Distance from 52-week high-22.55%-66.12%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+49.29%+361.94%
Average volume373.16K3.03M
Shares outstanding32.36M220.02M
Employees62325
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • LBRX has outperformed OCUL by 207.9 percentage points over the past year.

About LB Pharmaceuticals

LBRX stock →

LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation.

Health Care · Biotechnology: Pharmaceutical Preparations · 62 employees

About Ocular Therapeutix

OCUL stock →

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.

Health Care · Biotechnology: Pharmaceutical Preparations · 325 employees

LBRX vs OCUL FAQ

Which is bigger, LB Pharmaceuticals or Ocular Therapeutix?

LB Pharmaceuticals (LBRX) is larger, with a market capitalization of $1.26B compared with $1.23B for Ocular Therapeutix (OCUL).

Which stock has performed better over the past year, LBRX or OCUL?

LBRX returned +153.42% over the past 12 months, compared with -54.49% for OCUL (price return, excluding dividends). Past performance does not predict future results.

Are LB Pharmaceuticals and Ocular Therapeutix in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons